Selected Articles from This Issue

In patients with unresectable stage III non-small cell lung cancer (NSCLC), the standard of care is concurrent chemoradiotherapy (CCRT) followed by durvalumab therapy within 1 to 42 days after CCRT completion. Preclinical studies have demonstrated that concomitant administration of CCRT and immunotherapy led to increased survival rates compared to sequential administration; however, simultaneous CCRT and immunotherapy treatment poses safety risks in patients. The optimal timeline for initiating immunotherapy after chemoradiotherapy has yet to be established. In this phase II study, Nakamichi and colleagues investigated the safety and efficacy of beginning durvalumab treatment immediately after chemoradiotherapy completion in patents with unresectable stage III NSCLC. The observed adverse events (AEs) were similar to previously reported AEs, and no unexpected AEs occurred. The response was encouraging, with the authors reporting an objective response rate of 78.7%, a 1-year progression-free survival (PFS) rate of 75.0%, and a median PFS of 14.2 months from registration....